Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.

[1]  J. Mascola,et al.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. , 2007, Vaccine.

[2]  D. Montefiori,et al.  A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2007, Journal of Virology.

[3]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[4]  R. Desrosiers,et al.  Induction of a virus-specific effector–memory CD4+ T cell response by attenuated SIV infection , 2006, The Journal of experimental medicine.

[5]  R. Ruprecht,et al.  AIDS vaccine development and challenge viruses: getting real. , 2006, AIDS.

[6]  D. Montefiori,et al.  An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains , 2006, Journal of acquired immune deficiency syndromes.

[7]  D. O’Connor,et al.  Control of Simian Immunodeficiency Virus SIVmac239 Is Not Predicted by Inheritance of Mamu-B*17-Containing Haplotypes , 2006, Journal of Virology.

[8]  D. Venzon,et al.  Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. , 2006, Virology.

[9]  L. Corey,et al.  HIV vaccines: new frontiers in vaccine development. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Mario Roederer,et al.  Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates , 2006, The Journal of experimental medicine.

[11]  M. Carrington,et al.  The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2006, Journal of Virology.

[12]  Shixia Wang,et al.  Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. , 2006, Virology.

[13]  D. Venzon,et al.  A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.

[14]  J. Shiver,et al.  Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys , 2005, Journal of Virology.

[15]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[16]  D. Montefiori,et al.  Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies , 2005, Journal of Virology.

[17]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[18]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[19]  D. Venzon,et al.  Vaccine-Elicited Antibodies Mediate Antibody-Dependent Cellular Cytotoxicity Correlated with Significantly Reduced Acute Viremia in Rhesus Macaques Challenged with SIVmac2511 , 2005, The Journal of Immunology.

[20]  J. Mascola,et al.  Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins , 2005, Journal of Virology.

[21]  V. Maino,et al.  Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.

[22]  J. Mascola,et al.  Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys , 2004, Journal of Virology.

[23]  D. Venzon,et al.  Protection against Mucosal Simian Immunodeficiency Virus SIVmac251 Challenge by Using Replicating Adenovirus-SIV Multigene Vaccine Priming and Subunit Boosting , 2004, Journal of Virology.

[24]  D. Venzon,et al.  Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. , 2003, Vaccine.

[25]  D. Venzon,et al.  Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120 , 2003, Journal of Virology.

[26]  D. Montefiori,et al.  Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge by a Replication-Competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag Recombinant Priming/gp120 Boosting Regimen , 2003, Journal of Virology.

[27]  Todd M. Allen,et al.  Expression of the Major Histocompatibility Complex Class I Molecule Mamu-A*01 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2003, Journal of Virology.

[28]  J. Shiver,et al.  Mamu-A*01 Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection , 2002, Journal of Virology.

[29]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[30]  C. Pitcher,et al.  Development and Homeostasis of T Cell Memory in Rhesus Macaque1 , 2002, The Journal of Immunology.

[31]  Charles R. Brown,et al.  Rapid and Irreversible CD4+ T-Cell Depletion Induced by the Highly Pathogenic Simian/Human Immunodeficiency Virus SHIVDH12R Is Systemic and Synchronous , 2002, Journal of Virology.

[32]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[33]  James G. Herndon,et al.  Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.

[34]  Andrew Gibson,et al.  Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. , 2000, Journal of virological methods.

[35]  K. Mansfield,et al.  Identifying the Target Cell in Primary Simian Immunodeficiency Virus (SIV) Infection: Highly Activated Memory CD4+ T Cells Are Rapidly Eliminated in Early SIV Infection In Vivo , 2000, Journal of Virology.

[36]  P. Kelley,et al.  Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. , 1998, The Journal of infectious diseases.

[37]  S. Zolla-Pazner,et al.  Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus , 1998, Journal of Virology.

[38]  R P Johnson,et al.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. , 1998, Science.

[39]  K. Steimer,et al.  Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees , 1998, Journal of Virology.

[40]  M. Robert-Guroff,et al.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge , 1997, Journal of virology.

[41]  S. Zolla-Pazner,et al.  Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization , 1997, Nature Medicine.

[42]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[43]  P. Roller,et al.  A Synthetic Conformational Epitope from the C4 Domain of HIV Gp120 That Binds CD4* , 1996, The Journal of Biological Chemistry.

[44]  P. Roller,et al.  A Helical Epitope in the C4 Domain of HIV Glycoprotein 120 (*) , 1995, The Journal of Biological Chemistry.